2025 Review: The Promise of Innovation, Fulfilled

2026-01-08

We’re excited to share some of the key milestones of LinkZill in 2025. Our long-standing commitment to technological innovation is now bearing fruit.

– Walden International has joined LinkZill as a new investor in the A+ round of financing. To date, LinkZill has secured investments from multiple leading investment institutions across the semiconductor and life sciences industries. We welcome more partners to join us in driving the industrialization and implementation of TFT semiconductor technology.

– Life Sciences BU: Launched TruSynth – The world’s first oligonucleotide microarray synthesizer based on TFT semiconductor technology, alongside TruArray and TruPool, achieving deployment in national key labs and securing major customer wins, marked a pivotal shift from R&D to commercial scale. More info: https://www.linkzill.com/en/life_sciences/

– Optoelectronic BU: Delivered an exceptional performance by expanding TruEbox shipments to ~200 units, achieved ~80% YoY growth in displays, driven by strong global demand. More info: https://www.linkzill.com/en/optoelectronics/

– Global Footprint: The UK subsidiary completed its first full year of operation; 30% of revenue is now derived from overseas markets, establishing a global revenue base.

We are grateful to everyone who has supported LinkZill on our journey. As we enter 2026, we look forward to building on these achievements, applying our cutting-edge TFT semiconductor technology to create practical solutions for innovators and enterprises worldwide, and reaching even greater milestones in productivity transformation and industry impact.

Dr. Kang Kang

Partner & CBio

Dr. Kang received his Ph.D. in Bioinformatics and Systems Biology from the University of Hong Kong in 2018, then became a scientific co-worker of the Leibniz Association (Leibniz-HKI) and a visiting scientist at the Novo Nordisk Foundation Center for Biosustainability (DTU Biosustain) at the Technical University of Denmark. He was a scientist at BGI-Shenzhen and co-founded the synthetic biology research group. He was a senior bioinformatics engineer and brand advisor at WeGene. In 2021, Kang joined Biosysen Limited as a co-founder and served as Chief Informatics Scientist. He is also an advisor and author of the biotech media "Regenesis". He has been dedicated to the R&D and industrialization of OMICs technologies, high-throughput technologies, and synthetic biology for over 10 years. He joined LinkZill in March 2023, responsible for semiconductor life science tools and product planning.

康康   博士

合伙人兼首席生物信息官

博士毕业于香港大学生物信息和系统生物学专业,后任德国莱布尼茨协会科学合作者、丹麦科技大学诺和诺德生物可持续研究中心访问科学家。曾先后担任华大基因科学家,参与创立了华大基因合成生物学研究方向;微基因资深生物信息工程师、品牌顾问;倍生生物联合创始人兼首席信息科学家。他专注于合成生物学、组学和高通量技术10余年,同时也是生物技术领域颇具影响力的「行业KOL」。2023年3月加入领挚科技,负责半导体生命科学工具方向与产品规划。